Harley Street InstituteJournal

    AI-Reviewed Research, Clinical Excellence & Evidence-Based Practice— Curated and reviewed by practising aesthetic clinicians

    Aesthetic Intelligence · Industry News

    Industry News for Aesthetic Medicine

    Regulatory updates, product alerts, peer-reviewed research highlights, and HSI announcements — filtered by region. Editorial commentary, not promotional.

    🌐All Regions🇬🇧United Kingdom🇮🇪Ireland🇺🇸United States🌍Global
    4 items
    Product🌍 Global•17 Jul 2026

    European Commission approves Boey (trenibotulinumtoxinE), the first serotype E neurotoxin in Europe

    Allergan Aesthetics announced on 17 July 2026 that the European Commission has approved Boey (trenibotulinumtoxinE) across all 30 EEA countries for the temporary improvement of moderate to severe glabellar lines in adults where these have an important psychological impact. It is the first rapid-onset, short-duration botulinum neurotoxin serotype E licensed in Europe, with onset observed as early as eight hours and effect typically resolving within two to three weeks; approval follows Health Canada authorisation in June 2026. Harley Street Institute has published a review explaining why serotype E duration is set by its SNAP-25 cleavage site and light-chain persistence rather than by dose.

    Source: European Medicines Agency
    Related article Source
    Product🌍 Global•15 Jun 2026

    Teoxane unveils babyGLOW subdermal injection technique at IMCAS Paris 2026

    Aesthetic manufacturer Teoxane presented the babyGLOW technique — a standardised, anatomy-based subdermal injection approach using Teosyal Puresense Redensity 1 — at the International Master Course on Ageing Science (IMCAS) in Paris. The method, refined with a board of over 20 expert injectors across six countries, is designed to support consistent product distribution while avoiding facial danger zones. Harley Street Institute notes that anatomy-guided subdermal placement has been integral to its teaching curriculum for several years.

    Source: IMCAS / Teoxane
    Source
    Research🌍 Global•1 Jun 2026

    JAMA Dermatology: randomised trial of polynucleotide skin boosters

    A multi-centre randomised controlled trial published in JAMA Dermatology reports statistically significant improvements in dermal hydration and elasticity at twelve weeks following a three-session polynucleotide protocol versus saline control.

    Source: JAMA Dermatology
    Related article Source
    Research🌍 Global•20 May 2026

    The Lancet Neurology: real-world data on onabotulinumtoxinA for chronic migraine

    A large prospective registry analysis confirms sustained reduction in monthly headache days under the PREEMPT protocol, with response rates broadly mirroring pivotal trial outcomes across diverse populations.

    Source: The Lancet Neurology
    Related article Source

    Industry news is curated by the HSI editorial board. Items summarise external regulatory, product, and peer-reviewed developments and link to primary sources. They do not constitute clinical guidance. For peer-reviewed analysis, see the main journal.